Stock Events

Stock Events

Redhill Biopharma 

$0.7163
0
+$0.01+1.3% Wednesday 05:06

Statistics

Day High
0.7163
Day Low
0.7163
52W High
1.08
52W Low
0.6958
Volume
300
Avg. Volume
-
Mkt Cap
4.36M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-150%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
286,000Revenue
-429,000Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RDHL.BOATS. It's not an investment recommendation.
Apple
13
AAPL
Microsoft
10
MSFT
NVIDIA
8
NVDA
Tesla
7
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie competes in the gastrointestinal and infectious disease markets, similar to Redhill's focus areas.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a strong presence in the development of antiviral drugs, directly competing with Redhill's infectious disease portfolio.
Merck
MRK
Mkt Cap366B
Merck is involved in creating therapies for infectious diseases, including treatments that could overlap with Redhill's product offerings.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad range of products that compete in the infectious disease space, making it a competitor to Redhill.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca operates in various therapeutic areas, including infections and gastrointestinal diseases, overlapping with Redhill's interests.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb develops drugs in areas that compete with Redhill's focus, including gastrointestinal diseases.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the infectious disease market.
Sanofi
SNY
Mkt Cap107.39B
Sanofi has a diversified portfolio that includes treatments for infectious diseases, competing with Redhill.
Novartis
NVS
Mkt Cap292.35B
Novartis offers medications in several areas, including those that compete with Redhill's therapeutic focus.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals focuses on innovative treatments, including for infectious diseases, making it a competitor to Redhill.

About

RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
Show more...
CEO
ISIN
US7574683014

Listings

STU
DE
2RH.STU
MU
DE
2RH.MU
BOATS
BOATS
RDHL.BOATS
F
DE
2RH.F

0 Comments

Share your thoughts

FAQ

What is Redhill Biopharma stock price today?▼
The current price of RDHL.BOATS is $0.72 USD — it has increased by +1.3% in the past 24 hours. Watch Redhill Biopharma stock price performance more closely on the chart.
What is Redhill Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Redhill Biopharma stocks are traded under the ticker RDHL.BOATS.
What is Redhill Biopharma market cap?▼
Today Redhill Biopharma has the market capitalization of 4.36M
What is Redhill Biopharma revenue for the last year?▼
Redhill Biopharma revenue for the last year amounts to 286,000 USD.
What is Redhill Biopharma net income for the last year?▼
RDHL.BOATS net income for the last year is -429,000 USD.
In which sector is Redhill Biopharma located?▼
Redhill Biopharma operates in the Other sector.
When did Redhill Biopharma complete a stock split?▼
The last stock split for Redhill Biopharma was on August 20, 2024 with a ratio of 1:25.